AbbVie tumbles on drug test disappointment, Bristol-Myers gains
AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor which makes a similar drug, have jumped. Market Domination Hosts Julie Hyman and Josh Lipton outline what investors need to know.
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for ...
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. Published first on TheFly ...
2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond ...
Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...
Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback